A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
← catalyst calendarNCT07214727 · readout in 1,295 d
Sponsored by Alnylam Pharmaceuticals (industry) · ALNY — their whole pipeline →. With Regeneron Pharmaceuticals.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
50estimated
Sites
13
Countries
Canada, Netherlands, Spain +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-15 | actual | When the study began enrolling |
| Primary completion | 2030-03-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-03-06 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alzheimer's Disease
Interventions
- Drug: ALN-5288
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFFrequency of Adverse Events (AEs)
measured Up to 32 months
Severity of AEs
measured Up to 32 months
Permalink · ALNY's whole pipeline · Catalyst calendar · Every registered study · What changed